Market Cap 509.76B
Revenue (ttm) 88.82B
Net Income (ttm) 14.07B
EPS (ttm) N/A
PE Ratio 20.23
Forward PE 19.33
Profit Margin 15.84%
Debt to Equity Ratio 0.50
Volume 6,922,600
Avg Vol 8,668,340
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 94%
Beta 0.36
Analysts Strong Sell
Price Target $207.88

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
JarvisFlow
JarvisFlow Dec. 15 at 1:24 PM
B of A Securities has updated their rating for Johnson & Johnson ( $JNJ ) to Neutral with a price target of 220.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 15 at 10:33 AM
$JNJ RSI: 68.43, MACD: 4.0324 Vol: 4.12, MA20: 203.67, MA50: 194.81 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 5:34 AM
Actionable Trade Alert for $JNJ: Market Context: $JNJ is currently trading at $211.58, showing strong momentum with an RSI of 66.67, indicating it is nearing overbought territory. The recent price action is above both the 30-day MA (199.19) and 50-day MA (195.71), suggesting bullish sentiment. The 60-day high of $212.27 is just above the current price, which may act as a resistance level. Directional Bias: Given the RSI and the proximity to the 60D high, we expect a potential pullback or consolidation before further upward movement. However, the overall trend remains bullish. Trade Plan: - Suggested Entry: $211.60 - Stop Loss: $204.00 (approximately 3.5% below entry) - Take Profit Targets: 1. $215.00 (1.14% ROI) 2. $218.00 (3.15% ROI) 3. $220.00 (4.01% ROI) To achieve at least a 17% ROI, consider leveraging options or increasing position size strategically. Monitor price action closely around the 60D high. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
RockyTSTH
RockyTSTH Dec. 15 at 4:15 AM
OPTION WATCHLIST 12/14/2025 $JPM - Stock in a strong uptrend and close to all time highs. Looking for calls above $320 for a move towards $330 and higher. Stock is decent at indicator level. $JNJ - Stock having a flag breakout on the daily time frame as stock makes all time highs. Looking for calls as long as $210 holds for a move towards $225 and higher. $BAC -St Another bank stock make new highs on the daily time frame. Stock in a strong uptrend. Looking for calls as long as $55 holds for a move towards $60 and higher. $ORCL - Stock testing recent lows at $185 but holding strong. Looking for puts here if that level breaks. Stock does have an earnings gap to fill to the upside. Calls above $200 look good as well. Below $185 we can see retest of $165 $MCD - Stock near all time highs making an ascending triangle pattern on the daily. Looking for breakout moves over $320 for a move towards $335 and higher. Stock is decent at indicator level.
0 · Reply
Suite510
Suite510 Dec. 15 at 1:14 AM
$JNJ $KVUE Party over, time to pay for 50 years of product liability Pivotal LA Trial Alleging J&J's Baby Powder Caused Ovarian Cancer Ends in $40M Verdict A Los Angeles Superior Court jury deliberated for one day before awarding $40 million, all compensatory damages, to two women.
0 · Reply
ceinos
ceinos Dec. 14 at 11:06 PM
$JNJ overbought
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 14 at 8:47 PM
Enter: $JNJ Calls Strike Price: $215 Expiry Date: JAN 09 2026 Buy in Price: $3.11 - $3.35 Sell Price: $5.13 Profit : +65% (Turn every $1 into $1.65) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 14 at 6:39 PM
$JNJ Trading at all-time high around $211, testing some significant levels. Volume has been solid, averaging around 8.9 million. Bullish momentum seems strong with recent price action.
0 · Reply
harmongreg
harmongreg Dec. 14 at 5:19 PM
Dragonfly Capital - 5 Trade Ideas for Monday: Bank of America, Johnson & Johnson, Lilly, Progressive and Walmart $BAC $JNJ $LLY $PGR $WMT and look at special Holiday Pricing Plans https://dragonflycap.com/5-trade-ideas-for-monday-bank-of-america-johnson-johnson-lilly-progressive-and-walmart/
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 14 at 3:07 PM
On 12/9/25 $JNJ issued a press release disclosing the results of their Phase 3 clinical trial of their new combo therapy (name is too long to repeat here) in R/R multiple myeloma. Apparently, J&J had presented at ASH. The J&J combo drug appears to produce meaningfully better clinical outcomes in R/R (relapsed/refractory) multiple myeloma compared to Carvykti from $LEGN The attachment compares the key clinical data points from the 2 trials side-by-side (at least as we see them). It was puzzling to see Morgan Stanley recommend LEGN last Friday after reviewing these data points. Based on these results, we suspect J&J will push their new combo therapy (if approved) versus Carvykti. While the brutal truth is there are enough multiple myeloma patients for multiple therapies, it is likely the clinical differences will eventually manifest in lower LEGN revenue estimates (thus raising multiples). Pushback welcome. Did we miss any clinical data point (outside of side-effects) More to come. $XBI $IBB
2 · Reply
Latest News on JNJ
Johnson & Johnson: Reliable Cash Flows, Moderate Expectations

Dec 11, 2025, 7:05 PM EST - 3 days ago

Johnson & Johnson: Reliable Cash Flows, Moderate Expectations


16 Quality Stocks to Own for a Volatile Market

Dec 1, 2025, 1:23 PM EST - 13 days ago

16 Quality Stocks to Own for a Volatile Market

CSCO LLY XOM


2 Top Dividend Stocks to Buy and Hold

Nov 30, 2025, 4:05 AM EST - 15 days ago

2 Top Dividend Stocks to Buy and Hold

BMY


Best Dividend Aristocrats For December 2025

Nov 29, 2025, 8:02 AM EST - 16 days ago

Best Dividend Aristocrats For December 2025

ABBV ABT ADM ADP AFL ALB AMCR


Dogs Of The Dow Continue Outperforming Broader Market

Nov 29, 2025, 1:45 AM EST - 16 days ago

Dogs Of The Dow Continue Outperforming Broader Market

AMGN DIA MAGS SPY


Wasatch Global Value Fund Q3 2025 Performance Review

Nov 28, 2025, 7:50 AM EST - 17 days ago

Wasatch Global Value Fund Q3 2025 Performance Review

BABA CNC DOX NVDA


3 Superb Dividend Stocks to Hold for the Next 20 Years

Nov 27, 2025, 6:30 AM EST - 18 days ago

3 Superb Dividend Stocks to Hold for the Next 20 Years

KO O


1 Reason Why Shares of Johnson & Johnson Are Surging This Month

Nov 21, 2025, 12:43 PM EST - 23 days ago

1 Reason Why Shares of Johnson & Johnson Are Surging This Month


Why Johnson & Johnson's Share Price Is Popping This Month

Nov 19, 2025, 12:24 PM EST - 25 days ago

Why Johnson & Johnson's Share Price Is Popping This Month


Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion

Nov 17, 2025, 8:29 AM EST - 4 weeks ago

Johnson & Johnson to Buy Halda Therapeutics For $3.05 Billion


Halda Therapeutics Announces Acquisition by Johnson & Johnson

Nov 17, 2025, 8:15 AM EST - 4 weeks ago

Halda Therapeutics Announces Acquisition by Johnson & Johnson


Bristol Myers, J&J halt heart drug trial after interim review

Nov 14, 2025, 8:03 AM EST - 4 weeks ago

Bristol Myers, J&J halt heart drug trial after interim review

BMY


2 Strong Healthcare Stock Picks for Dividend Investors

Nov 13, 2025, 3:55 AM EST - 4 weeks ago

2 Strong Healthcare Stock Picks for Dividend Investors

ABBV


Johnson & Johnson: Dividends Don't Lie

Nov 7, 2025, 5:40 AM EST - 5 weeks ago

Johnson & Johnson: Dividends Don't Lie


Cramer's Mad Dash: Johnson & Johnson

Nov 6, 2025, 9:54 AM EST - 5 weeks ago

Cramer's Mad Dash: Johnson & Johnson


US FDA expands use of J&J's Caplyta as add-on depression drug

Nov 6, 2025, 7:34 AM EST - 5 weeks ago

US FDA expands use of J&J's Caplyta as add-on depression drug


JarvisFlow
JarvisFlow Dec. 15 at 1:24 PM
B of A Securities has updated their rating for Johnson & Johnson ( $JNJ ) to Neutral with a price target of 220.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 15 at 10:33 AM
$JNJ RSI: 68.43, MACD: 4.0324 Vol: 4.12, MA20: 203.67, MA50: 194.81 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 15 at 5:34 AM
Actionable Trade Alert for $JNJ: Market Context: $JNJ is currently trading at $211.58, showing strong momentum with an RSI of 66.67, indicating it is nearing overbought territory. The recent price action is above both the 30-day MA (199.19) and 50-day MA (195.71), suggesting bullish sentiment. The 60-day high of $212.27 is just above the current price, which may act as a resistance level. Directional Bias: Given the RSI and the proximity to the 60D high, we expect a potential pullback or consolidation before further upward movement. However, the overall trend remains bullish. Trade Plan: - Suggested Entry: $211.60 - Stop Loss: $204.00 (approximately 3.5% below entry) - Take Profit Targets: 1. $215.00 (1.14% ROI) 2. $218.00 (3.15% ROI) 3. $220.00 (4.01% ROI) To achieve at least a 17% ROI, consider leveraging options or increasing position size strategically. Monitor price action closely around the 60D high. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
RockyTSTH
RockyTSTH Dec. 15 at 4:15 AM
OPTION WATCHLIST 12/14/2025 $JPM - Stock in a strong uptrend and close to all time highs. Looking for calls above $320 for a move towards $330 and higher. Stock is decent at indicator level. $JNJ - Stock having a flag breakout on the daily time frame as stock makes all time highs. Looking for calls as long as $210 holds for a move towards $225 and higher. $BAC -St Another bank stock make new highs on the daily time frame. Stock in a strong uptrend. Looking for calls as long as $55 holds for a move towards $60 and higher. $ORCL - Stock testing recent lows at $185 but holding strong. Looking for puts here if that level breaks. Stock does have an earnings gap to fill to the upside. Calls above $200 look good as well. Below $185 we can see retest of $165 $MCD - Stock near all time highs making an ascending triangle pattern on the daily. Looking for breakout moves over $320 for a move towards $335 and higher. Stock is decent at indicator level.
0 · Reply
Suite510
Suite510 Dec. 15 at 1:14 AM
$JNJ $KVUE Party over, time to pay for 50 years of product liability Pivotal LA Trial Alleging J&J's Baby Powder Caused Ovarian Cancer Ends in $40M Verdict A Los Angeles Superior Court jury deliberated for one day before awarding $40 million, all compensatory damages, to two women.
0 · Reply
ceinos
ceinos Dec. 14 at 11:06 PM
$JNJ overbought
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 14 at 8:47 PM
Enter: $JNJ Calls Strike Price: $215 Expiry Date: JAN 09 2026 Buy in Price: $3.11 - $3.35 Sell Price: $5.13 Profit : +65% (Turn every $1 into $1.65) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 14 at 6:39 PM
$JNJ Trading at all-time high around $211, testing some significant levels. Volume has been solid, averaging around 8.9 million. Bullish momentum seems strong with recent price action.
0 · Reply
harmongreg
harmongreg Dec. 14 at 5:19 PM
Dragonfly Capital - 5 Trade Ideas for Monday: Bank of America, Johnson & Johnson, Lilly, Progressive and Walmart $BAC $JNJ $LLY $PGR $WMT and look at special Holiday Pricing Plans https://dragonflycap.com/5-trade-ideas-for-monday-bank-of-america-johnson-johnson-lilly-progressive-and-walmart/
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Dec. 14 at 3:07 PM
On 12/9/25 $JNJ issued a press release disclosing the results of their Phase 3 clinical trial of their new combo therapy (name is too long to repeat here) in R/R multiple myeloma. Apparently, J&J had presented at ASH. The J&J combo drug appears to produce meaningfully better clinical outcomes in R/R (relapsed/refractory) multiple myeloma compared to Carvykti from $LEGN The attachment compares the key clinical data points from the 2 trials side-by-side (at least as we see them). It was puzzling to see Morgan Stanley recommend LEGN last Friday after reviewing these data points. Based on these results, we suspect J&J will push their new combo therapy (if approved) versus Carvykti. While the brutal truth is there are enough multiple myeloma patients for multiple therapies, it is likely the clinical differences will eventually manifest in lower LEGN revenue estimates (thus raising multiples). Pushback welcome. Did we miss any clinical data point (outside of side-effects) More to come. $XBI $IBB
2 · Reply
AlertsAndNews
AlertsAndNews Dec. 13 at 8:58 PM
$JNJ U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care "Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mutated mCSPC"
1 · Reply
ripster47
ripster47 Dec. 13 at 7:23 PM
🚨 Find Opportunities that can grow your account substantially by doing 1 THING > Run Your Evening Scans > Find Biggest Up or Down HUGE MOVER > Plan for Day2 Repeatable Setup > Follow the Plan/Ride Clouds Winner 1 : $JNJ 200 Psych to 211 Learn HOW we did @TENETTRADEGROUP 👇 https://x.com/i/status/1999920374520152372
0 · Reply
Suite510
Suite510 Dec. 13 at 4:31 PM
$JNJ $KVUE $SPX JNJ legal team yesterday 🤣 jury took only a few hours 🤣 Cheers 🥂 Where’s Jim Cramer?
0 · Reply
Suite510
Suite510 Dec. 13 at 12:49 PM
$JNJ $KVUE Powerful Statement below estimated future legal liabilities $30B to $50B This verdict sends an unmistakable message that no amount of legal maneuvering or corporate intimidation will prevent juries from holding J&J accountable," Leigh O'Dell, Co-Lead of the MDL Plaintiffs’ Steering Committee, said. “The truth came out in this courtroom, and the scientific evidence accumulated over the years is powerful. We will not stop until every woman harmed by J&J's talc products receives the justice she deserves."
1 · Reply
FITTEST_RETAIL_TRADER
FITTEST_RETAIL_TRADER Dec. 13 at 5:26 AM
0 · Reply
FITTEST_RETAIL_TRADER
FITTEST_RETAIL_TRADER Dec. 13 at 5:08 AM
JNJ 220 is on the way
0 · Reply
FITTEST_RETAIL_TRADER
FITTEST_RETAIL_TRADER Dec. 13 at 5:07 AM
0 · Reply
Suite510
Suite510 Dec. 13 at 5:04 AM
$JNJ $KVUE The Los Angeles Superior Court jury granted $18 million to Monica Kent and $22 million to Deborah Schultz and her husband after finding that Johnson & Johnson had known for decades about potential risks from its talc products but did not warn consumers. According to Reuters, the verdict was delivered on Friday, 12 December 2025.
1 · Reply
Suite510
Suite510 Dec. 13 at 5:01 AM
$JNJ $KVUE lol 😂 hits keep coming watch for real bankruptcy soon California jury awards $18 million to Monica Kent and $22 million to Deborah Schultz and her husband. Plaintiffs claim decades of baby powder use caused ovarian cancer; J&J denies risk and plans to appeal. J&J faces over 67,000 talc-related lawsuits, including ovarian cancer and mesothelioma claims.
0 · Reply
Suite510
Suite510 Dec. 13 at 4:54 AM
$JNJ $KVUE here’s another if you can’t read California Jury Awards $40 Million in Landmark Talc Verdict Against Johnson & Johnson 2 plaintiffs Awarded 20M EACH Provided by Business Wire Dec 12, 2025 at 9:57:00 PM
0 · Reply
Suite510
Suite510 Dec. 13 at 4:49 AM
$JNJ $KVUE dopey idiot knows nothing about liability 😂 Pivotal LA Trial Alleging J&J's Baby Powder Caused Ovarian Cancer Ends in $40M Verdict A Los Angeles Superior Court jury deliberated for one day before awarding $40 million, all compensatory damages, to two women. 2 minute read December 12, 2025 at 08:48 PM
0 · Reply
Suite510
Suite510 Dec. 13 at 4:46 AM
$JNJ $KVUE lol liability estimated $30B to $50B A California jury on Friday awarded $40M to two women who said Johnson & Johnson’s baby powder was to blame for their ovarian cancer
0 · Reply